Ams W, Cuvelier ME, Berset C: Use of totally free radical approach to evaluate antioxidant activity. Lebensm-Wiss Technol 1995, 28:25?0. 47. Chiang LC, Chiang W, Chang MY, Ng LT, Lin CC: Antileukimic activity selected natural merchandise in Taiwan. Am J Chin Med 2003, 31:37?six. 48. Repetto G, del Peso A, Zurita JL: Neutral red uptake assay for the estimation of cell viability/cytotoxicity. Nat Protoc 2008, 3:1125?131. 49. Lee CC, Houghton P: Cytotoxicity of plants from Malaysia and Thailand applied traditionally to treat cancer. J Ethanopharmacol 2005, one hundred:237?43. 50. Boik J: Natural compounds in cancer therapy. Minnesota, USA: Oregon Medical Press; 2001. 51. Sri Nurestri AM, Sim KS, Norhanom AW, Hashim Y: Phytochemical and cytotoxic investigations of Pereskia grandifolia Haw. (Cactaceae) leaves. J Biol Sci 2009, 9:488?93. 52. Takeara R, Jimenez Computer, Wilke DV, Odorico de Moraes M, Pessoa C, Peporine Lopes N, Lopes JLC, Monteiro da Cruz Lotufo T, Costa Lotufo LV: Antileukemic effects of Didemnum psammatodes (Tunicata: Ascidiacea) constituents. Comp Biochem Physiol A Mol PKC Activator manufacturer Integr Physiol 2008, 151:363��369. 53. Miret S, De Groene EM, Klaffke W: Comparison of in vitro assays of cellular toxicity inside the human hepatic cell line HepG2. J Biomol Screen 2006, 11:184?93. 54. Syed Abd Rahman SN, Abdul Wahab N, Abd Malek SN: In vitro morphological assessment of apoptosis induced by antiproliferative constituents in the rhizomes of Curcuma zedoria. Evid Based Complement Alternat Med 2013, 2013:14.doi:ten.1186/1472-6882-13-243 Cite this NF-κB Inhibitor Formulation article as: Phang et al.: Antioxidant potential, cytotoxic activity and total phenolic content material of Alpinia pahangensis rhizomes. BMC Complementary and Option Medicine 2013 13:243.Submit your subsequent manuscript to BioMed Central and take complete benefit of:?Convenient on the web submission ?Thorough peer critique ?No space constraints or colour figure charges ?Immediate publication on acceptance ?Inclusion in PubMed, CAS, Scopus and Google Scholar ?Research that is freely out there for redistributionSubmit your manuscript at biomedcentral/submit
Drugs R D (2014) 14:177?84 DOI 10.1007/s40268-014-0055-ORIGINAL Research ARTICLESwitching a-Glucosidase Inhibitors to Miglitol Reduced Glucose Fluctuations and Circulating Cardiovascular Disease Threat Things in Sort 2 Diabetic Japanese PatientsNatsuyo Hariya ?Kazuki Mochizuki ?Seiya Inoue ?Miyoko Saito ?Masahiro Fuchigami Toshinao Goda ?Takeshi Osonoi?Published on the internet: 31 July 2014 ?The Author(s) 2014. This short article is published with open access at SpringerlinkAbstract Background and Objectives Within this study we examined the effects of switching a-glucosidase inhibitors (a-GI) from acarbose or voglibose to miglitol on glucose fluctuations and circulating concentrations of cardiovascular disease risk things, like soluble adhesion molecules (sE-selectin, sICAM-1 and sVCAM-1), a chemokine monocyte chemoattractant protein (MCP)-1, plasminogen activator inhibitor-1, and fatty acid-binding protein 4, in sort 2 diabetic sufferers for 3 months. Techniques We enrolled 47 Japanese patients with kind two diabetes, with HbA1c levels with 7.26 ?0.five (imply ?normal deviation), and who have been treated together with the highest approved dose of acarbose (100 mg/meal) or voglibose (0.3 mg/meal) in combination with insulin or sulfonylurea.N. Hariya Division of Engineering, Interdisciplinary Graduate College of Medicine and Engineering, University of Yamanashi, Kofu, Japan K. Mochizuki ?S. Inoue ?T. Goda Division of Meals and Nutrition.
